FluoroPharma Medical Inc. announced that it has been collaborating with Royal Philips for data management in conjunction with its Phase II clinical trials for its lead agent CardioPET (18-F FCPHA). The CardioPET image data was put through a rigorous quality assurance process. For this, FluoroPharma collaborated with Philips and its Advanced Molecular Imaging technology to ensure that uniform standards were carefully applied to data from their advanced imaging systems across clinical sites.